A Cross Sectional Evaluation of Vitamin D Status and Ovarian Reserve Markers

NCT ID: NCT05137964

Last Updated: 2021-11-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

199 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-01

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the association between vitamin D (VD) deficiency and ovarian reserve markers in a group of Pakistani sub fertile women was conducted

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective

This study was conceived with the objective to assess ovarian reserves in presence of vitamin D deficiency (VDD) in a select group of Pakistani sub fertile women, presenting at a specialized fertility centre. The measurements of antral follicle count (AFC), Serum Anti-Müllerian hormone (AMH), Serum Follicle-stimulating hormone (FSH) and Serum Vitamin D (VD) levels were the main tools used for the assessment of ovarian reserve.

Materials \& Methods A retrospective cross-sectional study was conducted at the Australian Concept Medical Centre after approval from the institutional ethical review committee. All female patients aged 18 to 45 years, presenting with primary and/or secondary subfertility, at the Australian Concept Medical Centre in Karachi, Pakistan from August 2016 to July 2021 were included in the study (n=301). Inclusion criteria was focused on subjects labelled as sub fertile by the consultant gynecologist, based on the criteria of failed to conceive after 12 months of no contraceptive use. Patients with missing data i.e., BMI, duration of subfertility, age, AMH, 25-hydroxyvitamin D (25-OHD), AFC and FSH were further excluded.

The Biochemical analysis was performed at the section of Chemical Pathology, department of Pathology and Laboratory Medicine, Aga Khan University, Karachi. 25-OHD was analyzed by a chemiluminescence assay on the liaison XL (DiaSorin) analyzer. AMH was measured using electro chemiluminescence assay on the Roche Diagnostic e411 analyzer. While FSH quantification was done using ADVIA Centaur FSH assay from Siemens Medical Solutions Diagnostics USA. The internal and external quality assurance was ensured according to the institutional protocol. Moreover, the laboratory is accredited by the College of American Pathologists (CAP) and Joint Commission international, ensuring external quality assurance.

AFC was determined through a transvaginal 2D ultrasound of the pelvis. To reduce the bias, all ultrasound scans were conducted in the center using the same machine (Model 6v1: Sonoscape) and vaginal probe (3.5 Hz). Before ultra sound procedure, patients were directed to empty bladder and a standard ultrasound technique was used. Two values were obtained, one for each ovary, and an average was taken to obtain a final value.

The data of all eligible patients was recorded in the pre-defined Performa designed for this study. The Kruskal-Wallis Test and one way ANOVA was applied to report the distribution of the data. The correlation between the categorical variables (25-OHD levels with AFC and AMH) was assessed using the Chi-Square test and Spearman Correlation. Comparison was based on 25-OHD levels grouped into three categories: deficiency (\<20ng/ml), insufficiency (21-29 ng/ml) and sufficiency (\>30ng/ml). AMH was categorized as low (\<1 ng/ml), low normal (1-2 ng/ml), normal (2-4 ng/ml), and high (\>4 ng/ml). The third variable, AFC, was also classified into very low (\<6), low normal (6-8), normal (8-10), high normal (10-12), very high (\>12). The p value \<0.05 was considered statistically significant. The statistical analysis was performed using the statistical software IBM SPSS Statistics for Windows version 23.0 (IBM Corp. Released 2015. Armonk, NY: IBM Corp).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subfertility, Female

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

subfertile female

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D Deficient

deficiency (\<20ng/ml)

Vitamin D

Intervention Type DIAGNOSTIC_TEST

Serum Biochemical routine lab workup and gynaecological ultra sound AFC

Vitamin D Sufficient

sufficiency (\>30ng/ml)

Vitamin D

Intervention Type DIAGNOSTIC_TEST

Serum Biochemical routine lab workup and gynaecological ultra sound AFC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D

Serum Biochemical routine lab workup and gynaecological ultra sound AFC

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Serum AMH, 25-hydroxyvitamin D (25-OHD), FSH and Antral Follicle Count (AFC) via ultra sound

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of primary and/or secondary subfertility

Exclusion Criteria

* Patients with missing data i.e., BMI, duration of subfertility, age, AMH, 25-hydroxyvitamin D (25-OHD), AFC and FSH.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Australian Concept Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Uzma Imran

Consultant Gyn Obs

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-07-01-Uzma Imran

Identifier Type: -

Identifier Source: org_study_id